Deletion of the 5'-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients.
Inclusion of the BCR-ABL ES probe in routine cytogenetics led to the identification of a subgroup of Philadelphia positive (Ph+) chronic myeloid leukaemia patients characterized by a 5'-ABL deletion. This anomaly was observed in 5/51 cases (9.8%). Cytological and clinical data suggest that the 5'-ABL deletion may be associated with dysplastic features of polymorphonuclear cells and metamyelocytes and a short chronic phase duration.
Herens
C
C
Departments of Human Genetics, Biological Haematology and Clinical Haematology, University of Liège, CHU, Sart Tilman, Liège, Belgium. christian.herens@chu.ulg.ac.be
Tassin
F
F
Lemaire
V
V
Beguin
Y
Y
Collard
E
E
Lampertz
S
S
Croisiau
C
C
Lecomte
M
M
De Prijk
B
B
Longrée
L
L
Koulischer
L
L
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015342:DNA Probes; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D017353:Gene Deletion; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome
D015342:DNA Probes; D016044:Fusion Proteins, bcr-abl